News - Cardio-vascular

Filter

Current filters:

Cardio-vascular

Popular Filters

469 to 493 of 516 results

AstraZeneca gets EU approval for Axanum; Merck & Co files ridaforolimus with EMA

02-08-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that it has received approval in…

Ariad PharmaceuticalsAstraZenecaAxanumCardio-vascularEuropeMerck & CoOncologyPharmaceuticalRegulationridaforolimus

Hypercholesterolemia therapeutics market forecast to show moderate growth

28-07-2011

The value of the global hypercholesterolemia therapeutics - cholesterol lowerers - market was put at…

Cardio-vascularMarkets & MarketingPharmaceuticalResearch

UK’s NICE backs use of TMC’s Angiox for STEMI patients undergoing primary PCI

27-07-2011

Following a previous positive draft guidance, the UK drugs watch dog the National Institute for Health…

AngioxCardio-vascularEuropePharmaceuticalPricingRegulationThe Medicines Company

Merck & Co gets North American and Mexican rights to vernakalant iv from Astellas

26-07-2011

US drug giant Merck & Co (NYSE: MRK) has entered into an agreement with Japan’s Astellas Pharma…

Astellas PharmaCardio-vascularCardiome PharmaLicensingMerck & CoNorth AmericaPharmaceuticalvernakalant

US FDA now joins in probe of Sanofi’s Multaq safety

25-07-2011

The US Food and Drug Administration says it is reviewing data from a clinical trial that was evaluating…

Cardio-vascularMultaqNorth AmericaPharmaceuticalRegulationSanofi

Merck & Co sets up China marketing JV with Simcere

22-07-2011

US pharma giant Merck & Co (NYSE: MRK) has signed a framework agreement with leading Chinese drugmaker…

Asia-PacificCardio-vascularDiabetesGenericsMarkets & MarketingMerck & CoPharmaceuticalSimcere Pharmaceutical

US FDA at last approves AstraZeneca blood-thinning drug Brilinta

21-07-2011

There was much awaited good news for Anglo-Swedish drug major AstraZeneca (LSE: AZN) last night, when…

AstraZenecaBrilintaCardio-vascularNorth AmericaPharmaceuticalRegulation

Daiichi Sankyo debuts Lixiana in Japan for VTE prevention after orthopedic surgery

20-07-2011

Building on its cardiovascular portfolio, Japanese drug major Daiichi Sankyo (TYO: 4568) has launched…

Asia-PacificCardio-vascularEisaiLixianaMarkets & MarketingPharmaceutical

Mixed Ph III results for Sanofi MS drug candidate Lemtrada; EMA to broaden review of Multaq

12-07-2011

French drug major Sanofi (Euronext: SAN) and its US biotech subsidiary Genzyme have announced mixed top-line…

AlemtuzumabBiotechnologyCardio-vascularEuropeGenzymeLemtradaMultaqPharmaceuticalRegulationResearchSanofi

Pfizer gains six months patent life for Lipitor on pediatric data; Bayer Yasmin patent scotched

11-07-2011

US drugs behemoth Pfizer (NYSE: PFE) could extend the European patent term for its al-time blockbuster…

BayerCardio-vascularEuropeGenericsLipitorPatentsPfizerPharmaceuticalReproductiveYasmin

CV events halt Sanofi Multaq trial; Merck KGaA drops Idera cancer drug on safety concerns

08-07-2011

In two clinical disappointments announced yesterday, French drug major Sanofi (Euronext: SAN) and Germany’s…

Cardio-vascularIdera PharmaceuticalsMerck KGaAMultaqOncologyPharmaceuticalResearchSanofi

US FDA approves Bayer and J&J’s Xarelto to help prevent DVT following hip/knee replacement surgery

04-07-2011

German drug major Bayer (BAY: DE) and US marketing partner Janssen Pharmaceuticals, a unit of Johnson…

BayerCardio-vascularJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Teva sold generic Lipitor in UK, despite ongoing patent proection, FT reports

04-07-2011

Despite the fact that US drugs behemoth Pfizer (NYSE: PFE) has patent protection for its blockbuster…

Cardio-vascularEuropeGenericsLipitorMarkets & MarketingPatentsPfizerTeva Pharmaceutical Industries

Pfizer and ChemRar plan to explore innovative R&D partnership in Russia

01-07-2011

Following in the footsteps of Switzerland’s Roche, global drugs behemoth Pfizer (NYSE: PFE) has…

Cardio-vascularChemRar Hi-TechOncologyPfizerPharmaceuticalResearch

AstraZeneca gets UK NICE backing for Brilique; collaborates with PTC for oncology and other potential drugs

30-06-2011

There was good news this morning for Anglo-Swedish drug major AstraZeneca (LSE: AZN), when the UK’s…

AstraZenecaBrilintaBriliqueCardio-vascularEuropeOncologyPharmaceuticalPTC TherapeuticsRegulationResearch

Lowering LDL cholesterol does not significantly slow down CKD progression

26-06-2011

There were some disappointing results from clinical trials for several current therapies presented at…

Cardio-vascularGastro-intestinalsPharmaceuticalResearch

Pfizer and B-MS’ blood thinner Eliquis better than expected in Ph III trial

24-06-2011

US drug majors Pfizer (NYSE: PFE) and Bristol-Myers Squibb (NYSE: BMY) had a significant boost when they…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalPradaxaResearchXarelto

Jubilant and AstraZeneca successful in delivery of early milestones in pain drug accord

23-06-2011

Jubilant Biosys, a Bengaluru-based subsidiary of India’s Jubilant Life Sciences, and Anglo-Swedish…

AstraZenecaCardio-vascularJubilantMetabolicsNeurologicalPharmaceuticalResearch

AstraZeneca close to selling dental unit; fewer deaths with Brilinta in ACS patients than with clopidogrel

21-06-2011

In a move that has been previously flagged, Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) is…

AstraZenecaBrilintaCardio-vascularMergers & AcquisitionsPharmaceuticalResearch

Positive draft guidance from UK’s NICE for GSK’s Trobalt and TMC’s Angiox

20-06-2011

The UK’s drug watchdog body the National Institute for Health and Clinical Excellence (NICE) last…

AngioxCardio-vascularEuropeGlaxoSmithKlineNeurologicalPharmaceuticalPricingRegulationThe Medicines CompanyTrobalt

Johnson & Johnson to take $500-$600 million charge as Cordis drops Cypher heart stents

17-06-2011

US health care giant Johnson & Johnson (NYSE: JNJ), which has suffered a steady stream of bad news relating…

Cardio-vascularFinancialJohnson & JohnsonPharmaceutical

US FDA curbs use of high-dose simvastatin, citing increased risk of muscle injury

09-06-2011

The US Food and Drug Administration yesterday announced safety label changes for the cholesterol-lowering…

Abbott LaboratoriesCardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationSimcorSimvastatinZocor

469 to 493 of 516 results

Company Spotlight

Fibrotech

Fibrotech

Back to top